Novartis Venture Fund Overview
- Investor Type
- Venture Capital
- Status
- Active
- Professionals
- 9
- Investments
- 309
- Portfolio
- 52
- Exits
- 141
Novartis Venture Fund General Information
Description
Founded in 1996, Novartis Venture Fund is a corporate venture capital arm of Novartis headquartered in Basel, Switzerland. The firm seeks to invest in the life sciences, oncology, biotechnology, and digital health sectors. The firm has an additional presence in Cambridge, Massachusetts.
Contact Information
Website
Year Founded
1996
Investor Status
Actively Seeking New Investments
Trade Association
National Venture Capital Association (NVCA)
Primary Investor Type
Corporate Venture Capital
Other Investor Types
Growth/Expansion
Impact Investing
Venture Capital
Primary Office
- Postfach
- 4002 Basel
- Switzerland
+41 061 000 00 00
Novartis Venture Fund Investments (309)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| Exo Therapeutics | 16-Dec-2020 | Early Stage VC | 0000 | Drug Discovery | Startup | 00000 000000 00.0 |
| 0000 000000000 | 10-Dec-2020 | 00000 00000 | 0000 | Other Healthcare Services | Startup | 00000 00000 00.0 |
| 0000000 | 10-Nov-2020 | 00000 00000 | 000.00 | Drug Discovery | Generating Revenue | 0000 0000000 |
| 000000 00000000000 | 13-Oct-2020 | 00000 00000 | 000.00 | Drug Discovery | Product Development | 0000 0000000 |
| 0000 (000000000000 | 21-Sep-2020 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | 000000 0000000000 |
| 000000 000 | 14-Sep-2020 | 00000 00000 | 0000 | Biotechnology | Clinical Trials - Phase 1 | |
| 0000000 00 | 20-Aug-2020 | 00000 00000 | 0000 | Other Healthcare Services | Generating Revenue | |
| 0000000-000 | 18-Aug-2020 | 00000 00000 | 0000 | Biotechnology | Generating Revenue | |
| GentiBio | 05-Aug-2020 | Seed Round | 0000 | Drug Discovery | Startup | 000000 0000000000 |
| FoRx Therapeutics | 22-Apr-2020 | Seed Round | 000.00 | Drug Discovery | Startup | 0000000 00000000000000 00.0 |
Novartis Venture Fund Exits (141)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Forma Therapeutics | 11-Dec-2020 | Public Investment 2nd Offering | 00000 |
| 0000000000 0000000 | 07-Oct-2020 | 000000000 00000000 | 000.00 |
| 000000000 | 21-Sep-2020 | 000000000000000000 | 00000 |
| 0000000 0000000000 | 24-Jul-2020 | 000 | 00000 |
| 000000 | 26-Jun-2020 | 000 | 00000 |
| 00000 000000000000 | 19-Jun-2020 | 000 | 00000 |
| 0000000 0000000 00 | 15-Jun-2020 | 0000000000: 000000 | |
| 0000000000 | 01-Apr-2020 | 000000000000000000 | |
| Microchips Biotech | 20-Nov-2019 | Merger/Acquisition | |
| Galera Therapeutics | 07-Nov-2019 | IPO | 0000 |
Novartis Venture Fund Investments by Industry, Year, and Region
Investments by Industry
Investments by Year
Investments by Region
PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.
Request a free trialNovartis Venture Fund Team (27)
| Name | Title | Deals | Funds | Boards | Office |
|---|---|---|---|---|---|
| Anja König Ph.D | Global Head | 00 | 0 | 0 | Basel, Switzerland |
| Bart Dzikowski | Managing Director & Head of Transactions & Legal | 0 | Basel, Switzerland | ||
| Aaron Nelson Ph.D | Managing Director | 0 | 0 | Cambridge, MA | |
| Florian Muellershausen Ph.D | Managing Director | 0 | 0 | Basel, Switzerland | |
| Laura Brass Ph.D | Managing Director | 0 | 0 | 0 | Cambridge, MA |
Novartis Venture Fund Co-Investors (195)
| Name | With | Exits | Lead Partner | Series | Industry |
|---|---|---|---|---|---|
| Johnson & Johnson Innovation - JJDC | 6 | 0 |
|
|
|
| AbbVie Ventures | 0 | 0 |
|
|
|
| Novo Holdings | 0 | 00 |
|
|
|
| OrbiMed | 0 | 0 |
|
|
|
| Life Sciences Partners | 0 | 0 |
|
|